Celystra Pharma

About Celystra Pharma

Celystra Pharma is a Quebec-based biopharmaceutical company launched in May 2026 to address unmet medical needs in the Canadian market. The company was established by three seasoned pharmaceutical industry executives: Paul Lévesque, Philippe Dubuc, and John Leasure. The venture is supported by over $20 million in initial investments from partners such as Investissement Québec and Crédit Mutuel Equity, in addition to contributions from the founders themselves. The leadership team's background is central to Celystra's strategy. CEO Paul Lévesque has over 40 years of industry experience, including roles as the Global President of Pfizer's Rare Disease Unit and, more recently, CEO of Theratechnologies. Co-founders Philippe Dubuc and John Leasure also held senior roles at Theratechnologies as CFO and Global Commercial Officer, respectively, with prior extensive careers at Pfizer and in corporate finance. Their collective expertise in rare diseases, commercialization, and finance underpins the company's business model, which focuses on identifying and in-licensing therapies from global partners to introduce them to underserved patient populations in Canada. Celystra's operational model centers on acquiring Canadian rights to promising drugs and navigating the national regulatory and commercialization pathways. The company's inaugural partnership is with Ionis Pharmaceuticals, securing the rights to two treatments for rare genetic conditions. The first, TRYNGOLZA® (olezarsen), is approved by Health Canada for Familial Chylomicronemia Syndrome (FCS), a condition with a notably higher prevalence within the French-Canadian population, particularly in eastern Quebec. The second drug, DAWNZERA® (donidalorsen), is intended to prevent attacks associated with Hereditary Angioedema (HAE) and is currently under regulatory review by Health Canada. This strategic focus on rare diseases aligns with Canadian federal and provincial government initiatives aimed at improving patient access to specialized treatments. Keywords: Celystra Pharma, biopharmaceutical, Canada, drug commercialization, in-licensing, rare diseases, specialty pharma, Paul Lévesque, Philippe Dubuc, John Leasure, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, DAWNZERA, donidalorsen, Familial Chylomicronemia Syndrome, FCS, Hereditary Angioedema, HAE, Health Canada, Quebec life sciences, Investissement Québec, Theratechnologies, Pfizer, Canadian healthcare market, underserved patients, genetic diseases, therapy acquisition, biopharma financing, Montreal, drug launch